Addressing drug effects on cut point determination for an anti-drug antibody assay

Journal of Immunological Methods

Volumn 384, Issue 1-2, 2012, Pages 152-156

  Barbosa, Maria D F S ^a   Gleason, Carol R ^b   Phillips, Kelli R ^c   Berisha, Flora ^a   Stouffer, Bruce ^a   Warrack, Bethanne M ^b   Chen, Guodong ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b BMS   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

ADA; Antibody; Assay; Confirmation; CP; Cut point; Drug tolerance; Immunogenicity

Indexed keywords

DRUG ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VALIDATION STUDY;

ANTIBODIES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOASSAY; KINETICS; NEOPLASMS;

EID: 84865589914     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.06.014     Document Type: Article

References (10)

1. EMA Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099362.pdf.
2. FDA Guidance for Industry. Assay Development for Immunogenicity Testing of Therapeutic Proteins http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf.
3. Hoffman D., Berger M. Statistical considerations for calculation of immunogenicity screening assay cut points. J. Immunol. Methods 2011, 373:200-208.
4. Li J.Y., Elliott R., Choi M., Lowe J., Wakshull E., Song A., Maia M. A competitive ligand-binding assay for detection of neutralizing antibodies to bevacizumab in human serum. AAPS National Biotechnology Conference. Poster Presentation 2011.
5. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
6. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.
7. Smith H.W., Butterfield A., Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul. Toxicol. Pharmacol. 2007, 49:230-237.
8. Smith H.W., Moxness M., Marsden R. Summary of confirmation cut point discussions. AAPS J. 2011, 13:227-229.
9. Swanson S.J., Chirmule N. Assessing specificity for immunogenicity assays. Bioanalysis 2009, 1:611-617.
10. Tatarewicz S., Miller J.M., Swanson S.J., Moxness M.S. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J. Immunol. Methods 2010, 357:10-16.